Ultra-Widefield Fluorescein Angiography to Monitor Therapeutic Response to Adalimumab in Behcet’s Uveitis

References

• Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N Engl J Med. 1999;341(17):1284–1291. doi:10.1056/NEJM199910213411707.
   PubMed Web of Science ®Google Scholar
• Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behcet’s disease. Semin Arthritis Rheum. 1998;27(4):197–217. doi:10.1016/S0049-0172(98)80001-2.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I. Behcet’s uveitis. Middle East Afr J Ophthalmol. 2009;16(4):219–224. doi:10.4103/0974-9233.58425.
   PubMedGoogle Scholar
• Atmaca LS. Fundus changes associated with Behcet’s disease. Graefes Arch Clin Exp Ophthalmol. 1989;227(4):340–344. doi:10.1007/BF02169409.
   PubMed Web of Science ®Google Scholar
• Ozdal PC, Ortac S, Taskintuna I, Firat E. Posterior segment involvement in ocular Behcet’s disease. Eur J Ophthalmol. 2002;12(5):424–431. doi:10.1177/112067210201200514.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–380. doi:10.1016/j.ajo.2004.03.022.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Akpek EK. Immunosuppression for posterior uveitis. Retina. 2005;25(1):1–18. doi:10.1097/00006982-200501000-00001.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513. doi:10.1016/S0002-9394(00)00659-0.
   PubMed Web of Science ®Google Scholar
• Kacmaz RO, Kempen JH, Newcomb C, et al. Ocular inflammation in Behcet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol. 2008;146(6):828–836. doi:10.1016/j.ajo.2008.06.019.
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Akazawa K, Nishioka Y, Sanui H, Inomata H, Nose Y. Prognostic factors of vision in patients with Behcet disease. Ophthalmology. 1995;102(2):317–321. doi:10.1016/S0161-6420(95)31022-6.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123(7):903–912. doi:10.1001/archopht.123.7.903.
   PubMedGoogle Scholar
• Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113:2317–2323.
   PubMed Web of Science ®Google Scholar
• Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89(5):533–536. doi:10.1136/bjo.2003.037192.
   PubMed Web of Science ®Google Scholar
• Rider P, Carmi Y, Cohen I. Biologics for targeting inflammatory cytokines, clinical uses, and limitations. Int J Cell Biol. 2016;2016:9259646. doi:10.1155/2016/9259646.
   PubMedGoogle Scholar
• Fabiani C, Vitale A, Emmi G, et al. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. Clin Rheumatol. 2019;38(1):63–70. doi:10.1007/s10067-018-4069-3.
   PubMed Web of Science ®Google Scholar
• LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. 2017;13(3):181–188. doi:10.1080/1744666X.2017.1288097.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi:10.1056/NEJMoa1509852.
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119(8):1575–1581. doi:10.1016/j.ophtha.2012.02.018.
   PubMed Web of Science ®Google Scholar
• Atmaca LS, Sonmez PA. Fluorescein and indocyanine green angiography findings in Behcet’s disease. Br J Ophthalmol. 2003;87(12):1466–1468. doi:10.1136/bjo.87.12.1466.
   PubMed Web of Science ®Google Scholar
• Yu HG, Kim MJ, Oh FS. Fluorescein angiography and visual acuity in active uveitis with Behcet disease. Ocul Immunol Inflamm. 2009;17(1):41–46. doi:10.1080/09273940802553279.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Llorenc V, Fontenla JR, Navarro MJ, Adan A. Use of ultra-wide-field retinal imaging in the management of active Behcet retinal vasculitis. Retina. 2014;34(10):2121–2127. doi:10.1097/IAE.0000000000000197.
   PubMed Web of Science ®Google Scholar
• Kim M, Kwon HJ, Choi EY, Kim SS, Koh HJ, Lee SC. Correlation between Fluorescein Angiographic findings and visual acuity in Behcet retinal vasculitis. Yonsei Med J. 2015;56(4):1087–1096. doi:10.3349/ymj.2015.56.4.1087.
   PubMed Web of Science ®Google Scholar
• Jones NP, Sala-Puigdollers A, Stanga PE. Ultra-widefield fundus fluorescein angiography in the diagnosis and management of retinal vasculitis. Eye (Lond). 2017;31(11):1546–1549. doi:10.1038/eye.2017.93.
   PubMed Web of Science ®Google Scholar
• Pecen PE, Petro KF, Baynes K, Ehlers JP, Lowder CY, Srivastava SK. Peripheral findings and retinal vascular leakage on ultra-widefield fluorescein angiography in patients with uveitis. Ophthalmol Retina. 2017;1(5):428–434. doi:10.1016/j.oret.2017.01.016.
   PubMedGoogle Scholar
• Moon SW, Kim BH, Park UC, Yu HG. Inter-observer variability in scoring ultra-wide-field fluorescein angiography in patients with Behcet retinal vasculitis. Ocul Immunol Inflamm. 2017;25(1):20–28. doi:10.1080/09273948.2016.1175640.
   PubMed Web of Science ®Google Scholar
• Criteria for diagnosis of Behcet’s disease. International study group for Behcet’s disease. Lancet. 1990;335(8697): 1078–1080.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature working G. standardization of uveitis nomenclature for reporting clinical data. results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–471. doi:10.1016/S0161-6420(85)34001-0.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi:10.1016/S0140-6736(16)31339-3.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Herbort CP, Khairallah M. Angiography scoring for uveitis working g. scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30(5):539–552. doi:10.1007/s10792-008-9263-x.
   PubMedGoogle Scholar
• Vitale A, Emmi G, Lopalco G, et al. Adalimumab effectiveness in Behcet’s disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol. 2017;36(2):451–455. doi:10.1007/s10067-016-3417-4.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Efficacy and safety of adalimumab in Behcet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):183–189. doi:10.1007/s10067-016-3480-x.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Vitale A, et al. Cumulative retention rate of adalimumab in patients with Behcet’s disease-related uveitis: a four-year follow-up study. Br J Ophthalmol. 2018;102(5):637–641. doi:10.1136/bjophthalmol-2017-310733.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Ozdal PC, Oray M, Onal S. Review for diagnostics of the year: Multimodal imaging in Behcet uveitis. Ocul Immunol Inflamm. 2017;25(1):7–19. doi:10.1080/09273948.2016.1205100.
   PubMed Web of Science ®Google Scholar
• Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. Br J Ophthalmol. 2011;95(9):1245–1250. doi:10.1136/bjo.2010.194464.
   PubMed Web of Science ®Google Scholar
• Keino H, Okada AA, Watanabe T, Nakayama M, Nakamura T. Efficacy of Infliximab for early remission induction in refractory uveoretinitis associated with Behcet disease: A 2-year follow-up study. Ocul Immunol Inflamm. 2017;25(1):46–51. doi:10.1080/09273948.2016.1239746.
   PubMed Web of Science ®Google Scholar
• Umazume A, Kezuka T, Usui Y, Suzuki J, Goto H. Evaluation of efficacy of infliximab for retinal vasculitis and extraocular symptoms in Behcet disease. Jpn J Ophthalmol. 2018;62(3):390–397. doi:10.1007/s10384-018-0589-2.
   PubMed Web of Science ®Google Scholar
• Campbell JP, Leder HA, Sepah YJ, et al. Wide-field retinal imaging in the management of noninfectious posterior uveitis. Am J Ophthalmol. e902. 2012;154(5):908–911. doi:10.1016/j.ajo.2012.05.019.
   PubMed Web of Science ®Google Scholar
• Leder HA, Campbell JP, Sepah YJ, et al. Ultra-wide-field retinal imaging in the management of non-infectious retinal vasculitis. J Ophthalmic Inflamm Infect. 2013;3(1):30. doi:10.1186/1869-5760-3-30.
   PubMedGoogle Scholar
• Kang HM, Lee SC. Long-term progression of retinal vasculitis in Behcet patients using a fluorescein angiography scoring system. Graefes Arch Clin Exp Ophthalmol. 2014;252(6):1001–1008. doi:10.1007/s00417-014-2637-z.
   PubMed Web of Science ®Google Scholar
• Namba K, Goto H, Kaburaki T, et al. A major review: current aspects of Ocular Behcet’s disease in Japan. Ocul Immunol Inflamm. 2015;23(Suppl 1):S1–23. doi:10.3109/09273948.2014.981547.
   PubMed Web of Science ®Google Scholar
• Campbell JP, Beardsley RM, Palejwala NV, et al. Peripheral vascular leakage in uveitis: clinical and angiographic findings. Ophthalmology. 2015;122(6):1269–1270. doi:10.1016/j.ophtha.2015.01.011.
   PubMed Web of Science ®Google Scholar
• Kaines A, Tsui I, Sarraf D, Schwartz S. The use of ultra wide field fluorescein angiography in evaluation and management of uveitis. Semin Ophthalmol. 2009;24(1):19–24. doi:10.1080/08820530802520095.
   PubMed Web of Science ®Google Scholar
• Herbort CP, Mantovani A, Bouchenaki N. Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up. Int Ophthalmol. 2007;27(2–3):173–182. doi:10.1007/s10792-007-9060-y.
   PubMedGoogle Scholar
• Onal S, Tugal-Tutkun I, Neri P, PH C. Optical coherence tomography imaging in uveitis. Int Ophthalmol. 2014;34(2):401–435. doi:10.1007/s10792-013-9822-7.
   PubMed Web of Science ®Google Scholar
• Tortorella P, D’Ambrosio E, Iannetti L, De Marco F, La Cava M. Correlation between visual acuity, inner segment/outer segment junction, and cone outer segment tips line integrity in uveitic Macular Edema. Biomed Res Int. 2015;2015:853728. doi:10.1155/2015/853728.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Iwasaki T, Kezuka T, et al. Functional and morphological changes in the eyes of Behcet’s patients with uveitis. Acta Ophthalmol. 2010;88(2):257–262. doi:10.1111/j.1755-3768.2009.01536.x.
   PubMed Web of Science ®Google Scholar